Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Sequential Phase I Study of MEK1/2 Inhibitors PD-0325901 or Binimetinib Combined With cMET Inhibitor PF-02341066 in Patients With RAS Mutant and RAS Wild Type (With Aberrant c-MET) Colorectal Cancer

Next Previous
Trial Profile

A Sequential Phase I Study of MEK1/2 Inhibitors PD-0325901 or Binimetinib Combined With cMET Inhibitor PF-02341066 in Patients With RAS Mutant and RAS Wild Type (With Aberrant c-MET) Colorectal Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary) ; Crizotinib (Primary) ; Mirdametinib (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MErCuRIC; MErCuRIC1

Most Recent Events

  • 10 Apr 2025 Results (n=56) assessing the safety, tolerability, objective responses, pharmacokinetic and pharmacodynamic parameters of binimetinib/crizotinib combination in patients with RAS mutant advanced colorectal cancer in dose escalation and dose expansion parts of this Ia/b study, published in the BMC Cancer.
  • 01 Oct 2019 Status changed from active, no longer recruiting to completed.
  • 28 Mar 2019 This trial has been completed in Ireland (2018-12-03) according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top